Loading clinical trials...
Loading clinical trials...
Phase II Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK-T-Cell Lymphoma
Conditions
Interventions
Etoposide
Ifosfamide
+4 more
Locations
2
South Korea
Samsung Medical Center
Seoul, Seoul, Korea, Republic of, South Korea
Samsung Medical Center
Seoul, South Korea
Start Date
February 21, 2016
Primary Completion Date
August 31, 2021
Completion Date
November 30, 2021
Last Updated
October 22, 2020
Lead Sponsor
Samsung Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions